

Title (en)

RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Title (de)

DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)

Title (fr)

INHIBITION DE L'EXPRESSION DU GENE BCL2 INDUITE PAR INTERFERENCE ARN AU MOYEN DE PETITS ACIDES NUCLEIQUES INTERFERENTS (SINA)

Publication

EP 1442143 A2 20040804 (EN)

Application

EP 03709164 A 20030218

Priority

- US 0304908 W 20030218
- US 35858002 P 20020220
- US 36312402 P 20020311
- US 38678202 P 20020606
- US 39690502 P 20020718
- US 40678402 P 20020829
- US 40837802 P 20020905
- US 40929302 P 20020909
- US 44012903 P 20030115

Abstract (en)

[origin: WO03070969A2] The present invention concerns methods and reagents useful in modulating BCL2 gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), doublestranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against BCL2, BCL-XL, MCL-1, BCL2-LI, CED-9, BAG-1, E1B-194 and/or BCL-A1 gene expression, useful in the treatment of cancer and any other condition that responds to modulation of BCL2, BCL-XL, MCL-1, BCL2-LI, CED-9, BAG-1, E1B-194 and/or BCL-A1 expression.

IPC 1-7

C12Q 1/68; C12P 19/34; C12N 15/63; C07H 21/02; C07H 21/04; A01N 43/04

IPC 8 full level

A61K 48/00 (2006.01); **A61P 1/04** (2006.01); **A61P 3/10** (2006.01); **A61P 7/00** (2006.01); **A61P 9/00** (2006.01); **A61P 17/06** (2006.01); **A61P 21/04** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/02** (2006.01); **C12N 15/09** (2006.01); **C12N 15/11** (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)

A61P 1/04 (2017.12); **A61P 3/10** (2017.12); **A61P 7/00** (2017.12); **A61P 9/00** (2017.12); **A61P 17/06** (2017.12); **A61P 21/04** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/02** (2017.12); **C12N 15/1135** (2013.01); **C12N 2310/111** (2013.01); **C12N 2310/14** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/317** (2013.01); **C12N 2310/318** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/322** (2013.01); **C12N 2310/332** (2013.01); **C12N 2310/346** (2013.01); **C12N 2310/53** (2013.01)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

DOCDB simple family (publication)

WO 03070969 A2 20030828; WO 03070969 A3 20040108; AU 2003213119 A1 20030909; CA 2463595 A1 20030828; EP 1442143 A2 20040804; EP 1442143 A4 20050216; JP 2005517452 A 20050616

DOCDB simple family (application)

US 0304908 W 20030218; AU 2003213119 A 20030218; CA 2463595 A 20030218; EP 03709164 A 20030218; JP 2003569860 A 20030218